N-Succinimidyl 3-maleimidopropionate - CAS 55750-62-4

N-Succinimidyl 3-maleimidopropionate - CAS 55750-62-4 Catalog number: BADC-01530

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Category
ADCs Linker
Product Name
N-Succinimidyl 3-maleimidopropionate
CAS
55750-62-4
Catalog Number
BADC-01530
Molecular Formula
C11H10N2O6
Molecular Weight
266.21
N-Succinimidyl 3-maleimidopropionate

Ordering Information

Catalog Number Size Price Quantity
BADC-01530 25 g $386
Inquiry
Description
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Synonyms
N-Succinimidyl 3-maleimidopropionate; BMPS; 2,5-Dioxopyrrolidin-1-yl 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoate; 3-(Maleimido)propionic acid N-hydroxysuccinimide ester; (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate; 3-Maleimidopropionic acid N-hydroxysuccinimide ester; 3-Maleimidopropionic Acid N-Succinimidyl Ester; BMPS Crosslinker; 3-Maleimido-propionic NHS ester
IUPAC Name
(2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate
Canonical SMILES
C1CC(=O)N(C1=O)OC(=O)CCN2C(=O)C=CC2=O
InChI
InChI=1S/C11H10N2O6/c14-7-1-2-8(15)12(7)6-5-11(18)19-13-9(16)3-4-10(13)17/h1-2H,3-6H2
InChIKey
JKHVDAUOODACDU-UHFFFAOYSA-N
Density
1.550±0.10 g/cm3 (Predicted)
Solubility
DMSO: ≥ 45 mg/ml (16904 mm)
Melting Point
168-170 °C
Flash Point
225.2°C
Index Of Refraction
1.605
LogP
-1.21550
PSA
101.06000
Biological Activity
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Clinical Trial Information
NCT NumberCondition Or DiseasePhaseStart DateSponsorStatus
NCT00829621Fractures, ClosedNot Applicable2016-11-06University of Missouri-ColumbiaCompleted
NCT02655120Aseptic Necrosis of Femur HeadNot Applicable2018-05-08University Hospital, LilleTerminated (stopping the marketing of BMP7)
NCT03769402Intrabony Periodontal DefectPhase 42018-12-07Ain Shams UniversityCompleted
NCT05025306Healing WoundPhase 32021-09-01Postgraduate Medical Institute, LahoreCompleted
NCT00405600Degenerative Lumbar Disc DiseaseNot Applicable2013-02-15Nova Scotia Health AuthorityCompleted
Appearance
White to off-white powder
Purity
98%
Shipping
Room temperature
Storage
solvent: -80°C 12 months; Powder: -20°C 3 years
Pictograms
Irritant
Signal Word
Warning
Boiling Point
448.8±47.0 °C (Predicted)
1. BMPs and the muscle-bone connection
Roberta Sartori, Marco Sandri Bone . 2015 Nov;80:37-42. doi: 10.1016/j.bone.2015.05.023.
Muscle and bone are two intimately connected tissues. A coordinated interplay between these tissues at mechanical levels is required for their development, function and ageing. Evidence is emerging that several genes and molecular pathways exert a pleiotropic effect on both muscle and bone. Bone morphogenetic proteins (BMPs) are secreted signal factors belonging to the transforming growth factor β (TGFβ) superfamily. BMPs have an essential role during bone and cartilage formation and maintenance. Recently, we and others have demonstrated that the BMP pathway also has a role in controlling adult skeletal muscle mass. Thus, BMPs become crucial regulators of both bone and muscle formation and homeostasis. In this review we will discuss the signalling downstream BMP and its role in muscle-bone interaction. This article is part of a Special Issue entitled "Muscle Bone Interactions".
2. Two Modulators of Skeletal Development: BMPs and Proteoglycans
B Frank Eames, Elham Koosha J Dev Biol . 2022 Apr 6;10(2):15. doi: 10.3390/jdb10020015.
During embryogenesis, skeletal development is tightly regulated by locally secreted growth factors that interact with proteoglycans (PGs) in the extracellular matrix (ECM). Bone morphogenetic proteins (BMPs) are multifunctional growth factors that play critical roles in cartilage maturation and bone formation. BMP signals are transduced from plasma membrane receptors to the nucleus through both canonical Smad and noncanonical p38 mitogen-activated protein kinase (MAPK) pathways. BMP signalling is modulated by a variety of endogenous and exogenous molecular mechanisms at different spatiotemporal levels and in both positive and negative manners. As an endogenous example, BMPs undergo extracellular regulation by PGs, which generally regulate the efficiency of ligand-receptor binding. BMP signalling can also be exogenously perturbed by a group of small molecule antagonists, such as dorsomorphin and its derivatives, that selectively bind to and inhibit the intracellular kinase domain of BMP type I receptors. In this review, we present a current understanding of BMPs and PGs functions in cartilage maturation and osteoblast differentiation, highlighting BMP-PG interactions. We also discuss the identification of highly selective small-molecule BMP receptor type I inhibitors. This review aims to shed light on the importance of BMP signalling and PGs in cartilage maturation and bone formation.
3. BMPs and their clinical potentials
Senyon Choe, Meejung Kim BMB Rep . 2011 Oct;44(10):619-34. doi: 10.5483/BMBRep.2011.44.10.619.
Bone morphogenetic protein (BMP) signaling in diseases is the subject of an overwhelming array of studies. BMPs are excellent targets for treatment of various clinical disorders. Several BMPs have already been shown to be clinically beneficial in the treatment of a variety of conditions, including BMP-2 and BMP-7 that have been approved for clinical application in nonunion bone fractures and spinal fusions. With the use of BMPs increasingly accepted in spinal fusion surgeries, other therapeutic approaches targeting BMP signaling are emerging beyond applications to skeletal disorders. These approaches can further utilize next-generation therapeutic tools such as engineered BMPs and ex vivo- conditioned cell therapies. In this review, we focused to provide insights into such clinical potentials of BMPs in metabolic and vascular diseases, and in cancer. [BMB reports 2011; 44(10): 619-634].
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Inquiry Basket